




Searching News Database: QNEXA
HSMN NewsFeed - 23 Dec 2011
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
HSMN NewsFeed - 5 Aug 2011
Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
HSMN NewsFeed - 25 May 2011
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
HSMN NewsFeed - 20 Dec 2010
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
HSMN NewsFeed - 3 May 2010
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 26 Mar 2010
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa(R) for the Treatment of Obesity
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa(R) for the Treatment of Obesity
HSMN NewsFeed - 29 Dec 2009
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
HSMN NewsFeed - 30 Jul 2007
KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist(TM)
KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist(TM)
HSMN NewsFeed - 21 Jun 2007
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
HSMN NewsFeed - 16 May 2007
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
HSMN NewsFeed - 1 Nov 2006
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
HSMN NewsFeed - 10 May 2006
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity